Introduction
Prostate cancer has the highest incidence and is the second leading cause of cancer death in men in the United States (Greenlee et al., 2000) . Androgen ablation, the standard therapy for metastatic prostate cancer, produces initially a dramatic reduction in tumor size, presumably because androgen-dependent cells undergo apoptosis. Most patients, however, eventually relapse into an androgen-insensitive state in which further anti-androgen therapy is ineective (Isaacs et al., 1994; Harris and Savill, 1995) . Therefore, there is an urgent need for novel and eective therapies for treatment of androgen-insensitive prostate cancer.
Retinoids are a class of natural and synthetic vitamin A analogs that regulate growth and dierentiation of normal, benign, and malignant cell types by modulating the activity of numerous genes through their binding to two distinct classes of nuclear retinoid receptors: retinoic acid (RA) receptors (RARs) and retinoid X receptors (RXRs). These receptors belong to the steroid hormone receptor superfamily, and each is further divided into three distinct subtypes: RAR a, b, and g and RXR a, b, and g (Chambon, 1996) . Upon ligand activation, these receptors bind the consensus cis response element named RA responsive element (RARE) or retinoid X responsive element (RXRE) located within the regulatory regions of a number of retinoid-regulated target genes (Chambon, 1996) . Because of their potent antiproliferative and dierentiation-and apoptosis-inducing eects, retinoids are promising agents for cancer chemoprevention and chemotherapy (Lotan, 1995) . However, the undesirable side eects caused by the broad biological activities of retinoids limit their long-term use as chemopreventive agents. Therefore, the pursuit of new retinoids with preferred preventive ecacy, therapeutic ecacy, or both and few side eects continues. The discovery of nuclear retinoid receptors as mediators of retinoid actions stimulated the development of receptor-selective retinoids as well as antagonists. Such compounds provide us not only the opportunity to identify a new generation of retinoids with few side eects and teratogenic risk but also tools to elucidate the complicated molecular mechanisms of action of retinoids.
One of these newly synthesized retinoids is 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437), which has RARg selectivity (Sun et al., 1997a) and has been shown to be very eective in inhibiting the growth of human lung (Sun et al., 1997b; Adachi et al., 1998b; Li et al., 1998) and breast cancer cells (Shao et al., 1995) , melanoma cells (Schadendorf et al., 1996) , and leukemia cells (Hsu et al., 1997) . The growth-inhibitory eects of CD437 have been proven to occur via induction of apoptosis through an RAR independent pathway (Shao et al., 1995; Sun et al., 1997b; Hsu et al., 1997) . In addition, CD437 was found to modulate the expression of some apoptosis-related genes such as p53, p21 (WAF1/CIP1), and bcl-2 in human lung cancer cells (Adachi et al., 1998b; Li et al., 1998; Sun et al., 1999a) and human breast cancer cells (Shao et al., 1995) . These results indicate that CD437 may have a unique mechanism of action that is dierent from the classic retinoid action observed in some cells.
Recently, CD437 was also reported to exert apoptosis-inducing activity in human prostate cancer (HPC) LNCaP and PC-3 cells (Liang et al., 1999) . In the present study, we compared and contrasted the apoptosis-inducing activity of CD437 in three HPC cell lines (LNCaP, PC-3 and Du145) and examined its eects on the expression of various genes implicated in apoptosis to approach its mechanism of action in HPC cells. We found that CD437 is eective in inducing apoptosis in HPC cells and identi®ed multiple genes that may be involved in CD437-induced apoptosis in HPC cells.
Results

CD437 exerts more potent growth inhibitory effects on androgen-independent HPC cells than on androgendependent HPC cells
The HPC cell lines used in this study included androgen-dependent LNCaP cells and androgen-independent PC-3 and DU145 cells. All-trans RA (ATRA), the natural retinoid, was almost ineective in inhibiting the growth of HPC cells, even at concentration up to 10 mM (Figure 1 ). In contrast, CD437 was very eective in inhibiting the growth of the three HPC cell lines, especially the androgen-independent ones, in a concentration-dependent fashion (Figure 1 ). The IC 50 values, the concentration at which cell number was decreased by 50%, for LNCaP, PC-3 and DU145 were 0.60+0.12, 0.20+0.03, and 0.34+0.12 mM, respectively. CD271, another RARb/g-selective retinoid with similar structure to CD437 (Sun et al., 1997a) , has been reported to exert potent eects on the growth of androgen-independent HPC cells (Lu et al., 1999) . We con®rmed this observation (Figure 1 ). However, we found that CD437 was almost 10-fold more potent than CD271 in inhibiting the growth of HPC cells (Figure 1 ).
Differential susceptibility of HPC cell lines to induction of apoptosis by CD437
Because in many cell types CD437 induces apoptosis, we next evaluated the apoptosis-inducing activity of CD437 in the HPC cells using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)-¯ow cytometry assay. The percentage of apoptotic cells (exhibiting increased FITC-dUTP incorporation) has risen from less than 10% in untreated cells to 40 ± 80% in cells treated with 1 mM CD437 for 48 h (Figure 2a,b) . Increased FITC-dUTP incorporation was detected early at 24 h after CD437 treatment, especially in PC-3 and DU145 cells ( Figure  2a ). Among the three HPC cell lines, DU145 cells were the most sensitive ones to CD437-induced apoptosis because approximate 50% apoptotic cells were already detected in DU145 cells whereas less than 30% and 10% apoptotic cells were detected in PC-3 and LNCaP cells, respectively, when treated with 1 mM CD437 for 24 h (Figure 2a ). The order of the susceptibility of the HPC cell lines to CD437-induced apoptosis was: DU1454PC-34LNCaP.
CD437 induces caspase-dependent or -independent apoptosis in HPC cells
The activation of caspases, especially that of caspase-3, and the cleavage of its substrates such as poly(ADPribose)polymerase (PARP), are hallmarks of apoptosis (Thornberry and Lazebnik, 1998) . Therefore, we examined the eects of CD437 on caspase-3 and PARP cleavage in the three HPC cell lines. As shown in Figure 3a , CD437 increased caspase-3 activity in DU145 and LNCaP cells. Caspase-3 activity was increased higher in DU145 cells than in LNCaP cells. However, only a minimal increase of caspase-3 activity was detected in CD437-treated PC-3 cells. Concomitantly, cleaved 89 kD PARP fragment was visualized at 16 and 32 h in DU145 cells and at 32 h in LNCaP cells, respectively, after treatment with CD437 ( Figure   Figure 1 Eects of CD437, CD271 and ATRA on the growth of HPC cells. Cells were seeded at densities of 2000 ± 6000 cells per well in 96-well culture plates. After 5 days of treatment with the indicated concentrations of retinoids, cell number was determined using Alamar Blue reagent as described in Materials and methods. Each point is the mean+s.d. of quadruplicate determinations Figure 2 Detection of CD437-induced apoptosis in HPC cells. Cells were plated in 10-cm diameter dishes and treated with 1 mM CD437 on the second day after seeding. Apoptosis was evaluated using the TUNEL assay as described in Materials and methods. (a) Time-course analysis of apoptosis induced by 1 mM CD437 in HPC cells. (b) A representative TUNEL result after the HPC cells were exposed to 1 mM CD437 for 48 h 3b). In contrast, no evidence for PARP cleavage could be detected at any time point (8, 16, 32 and 48 h) after exposure of PC-3 cells to CD437 (data not shown). Furthermore, we examined apoptosis induction by CD437 in the presence of the caspase-3 inhibitor Z-DEVD-FMK or the pan-caspase inhibitor Z-VAD-FMK in these three HPC cell lines. CD437-induced apoptosis was abolished or suppressed by these caspase inhibitors in DU145 and LNCaP cells but not in PC-3 cells (Figure 3c ). Taken together, these results indicate that CD437 induces either caspase-dependent (DU145 and LNCaP) or caspase-independent (PC-3) apoptosis in dierent HPC cells.
Modulation of the expression of p53, p21 and bcl-2 family genes by CD437 in HPC cells
To begin to understand the mechanism of CD437-induced apoptosis in HPC cells, the expression of a series of apoptosis-associated genes and their modulation by CD437 were analysed by either Western or Northern blotting depending on the availability of probes and antibodies. Time-course analysis of changes in gene expression after treatment with 1 mM CD437 was performed starting from 4 h to 32 h ( Figure 4 ). As shown in Figure 4a , CD437 increased p53 protein level in LNCaP cells, which possess wild-type p53, but not in DU145 and PC-3 cells, which express a mutated p53 and no p53, respectively. The eect of CD437 on p53 protein level was detected as early as 8 h after its addition to LNCaP cells. p21 exhibited a complex pattern of modulation by CD437. The p21 protein level was upregulated in LNCaP and PC-3 cells, whereas it decreased after a temporary increase at 8 h in DU145 cells by CD437 (Figure 4a ). In contrast, p21 mRNA level increased in all three HPC cell lines after CD437 treatment ( Figure 4b ).
Because p21 can be cleaved by caspase-3 during apoptosis (Chai et al., 2000; Gervais et al., 1998; Levkau et al., 1998) , we wondered whether the decreased p21 protein level in CD437-treated DU145 cells is due to its degradation. Therefore, we harvested both¯oating and attached DU145 cells after exposure to CD437 and examined p21 protein level again using Western blotting. As shown in Figure 4c , we detected a low molecular weight band (approximately 14 kDa) in CD437-treated cells, which is identical to cleaved p21 fragment reported previously (Chai et al., 2000; Gervais et al., 1998) . This suggests that p21 is cleaved during CD437-induced apoptosis in DU145 cells.
The levels of the anti-apoptotic bcl-2 protein and its family member bcl-X L were not changed by 1 mM CD437 in LNCaP cells whereas bcl-X L was just slightly decreased in DU145 and PC-3 cells after longer treatment (32 h) ( Figure 4a ). Compared with PC-3 cells, DU145 had a very low level of constitutively expressed bcl-2. The pro-apoptotic Bax protein was not detected in DU145 cells and its expression was not modulated by 1 mM CD437 in any of the three HPC cell lines (Figure 4a ).
Modulation of the expression of the oncogenes c-Myc, c-Jun, c-Fos, and the c-Myc target ornithine decarboxylase (ODC) by CD437 in HPC cells
The levels of c-Myc, c-Fos, and c-Jun mRNAs were increased by 1 mM CD437 in DU145 and PC-3 cells ( Figure 5 ). This eect was detected at 4 h, reached a Modulation of the expression of the death receptors Fas, DR4 and DR5 by CD437 in HPC cells CD437 modulated the expression of the three death receptor genes DR4, DR5 and Fas to a dierent degree in the dierent HPC cell lines (Figure 6 ). Fas expression was increased by CD437 in LNCaP and DU145 cells but not in PC-3 cells. Fas expression was increased at 4 h in LNCaP cells whereas it increased only after an 8-h treatment in DU145 cells. Interestingly, DR4 was rapidly and strongly induced in DU145 cells but only weakly in in PC-3 and LNCaP cells whereas DR5 was induced in all the three HPC cell lines. Although the increase in DR5 was observed at 4 h in the three cell lines, the levels of DR5 induction in the three HPC cell lines varied. CD437 induced increases in DR5 expression of 200, 100 and 50% in DU145, PC-3 and LNCaP cells, respectively ( Figure  6b ).
Synergistic induction of apoptosis by combination of CD437 and TRAIL or Fas ligand in HPC cells
Because both DR4 and DR5 can function as receptors for tumor necrotsis factor (TNF)-related apoptosisinducing ligand (TRAIL), which induces rapid apoptosis in a variety of cancer cells (Pitti et al., 1996; Ashkenazi et al., 1999; Gazitt, 1999) , it was plausible to assume that CD437 may enhance TRAIL-induced apoptosis in HPC cells, especially in DU145 cells. Therefore, we examined the eects of combination of CD437 and TRAIL on apoptosis induction in the HPC cells. Indeed, synergistic induction of apoptosis was detected in DU145 cells (Figure 7a ) but not in PC-3 cells and LNCaP cells (data not shown) when cell were treated with 0.3 mM CD437 and TRAIL ranging from Figure 4 Modulation of the expression of p53, p21, bax, bcl-2 and bcl-X L by CD437 in HPC cells. Cells were treated with 1 mM CD437 for the given times on the second day after seeding. Whole cell lysates from attached (a) or attached plus¯oating (c) cells and total RNA (b) were prepared, and Western and Northern blottings were performed as described in Materials and methods. (a) Western blot results for p53, p21, bax, bcl-2 and bcl-X L protein expression. The same membrane was repeatedly probed, stripped, and reprobed with dierent antibodies. Level of actin was used as a control for loading. The lane on the right (P) was loaded with an extract of CD437-treated H460 cells that serve as a positive control for the dierent proteins. (b) Northern blot analysis for p21 mRNA expression. Thirty mg/lane was loaded. The exposure times for LNCaP, DU145 and PC-3 cells were 17 h, 22 h and 24 h, respectively. GAPDH mRNA level was determined to compare loading and transfer in dierent lanes. (c) Western blot analysis for detection of cleaved p21 fragment in cell lysates from DU145 cells treated with 1 mM CD437 for 32 h 10 to 40 ng/ml. However, similar eect could be observed in PC-3 cells when CD437's concentration was increased to 0.5 mM (Figure 7a) . In LNCaP cells, We failed to detect any synergistic eect on induction of apoptosis when treated with a combination of higher concentrations of CD437 (0.5 and 1 mM) and TRAIL (100 ± 300 mg/ml) (data not shown).
Similarly, we examined the eect of combination of CD437 and Fas ligand (FasL) on apoptosis induction in LNCaP and DU145 cells because Fas is the receptor of FasL and CD437 upregulates Fas expression in these two cell lines. As shown in Figure 7b , synergistic induction of apoptosis was observed in LNCaP and DU145 cells when the cells were treated with the combination of CD437 and FasL.
Because CD437 induces dierent degrees of DR5 and DR4 expression in PC-3 and DU145 cells and synergistic induction of apoptosis were observed in Figure 5 Modulation of Myc, c-Jun, c-Fos and ODC expression by CD437 in HPC cells. Cells were treated on the second day after seeding with 1 mM CD437 for the indicated times. Total RNA was isolated and subjected to Northern blotting using 30 mg per lane. GAPDH mRNA level was determined to compare loading and transfer in dierent lanes Figure 6 Modulation of the expression of the death receptors Fas, DR4 and DR5 by CD437 in HPC cells. Cells were treated on the second day after seeding with 1 mM CD437 for the indicated times. Total RNA was isolated and subjected to Northern blotting using 30 mg per lane. GAPDH mRNA level was determined to compare loading and transfer in dierent lanes. (a) Northern blot results. (b) Quantitation of relative mRNA levels of death receptors that were normalized to GAPDH mRNA both cell lines when treated with the combination of CD437 and TRAIL, we wondered whether induction of these receptors was involved in apoptosis induction. Therefore, we investigated the eect of the combination of CD437 and TRAIL in the presence of soluble recombinant human decoy receptor 2 (DcR2) protein, which has only truncated death domain and thereby can compete with DR4 and DR5 for binding to prevent TRAIL-induced apoptosis (Ashkenazi and Dixit, 1998) , Figure 7c shows that synergistic induction of apoptosis by CD437 and TRAIL combination was suppressed by DcR2 in both cell lines, suggesting that CD437 augments TRAIL-induced apoptosis through upregulation of DR5 and/or DR4 in HPC cells.
Discussion
In this study, we have demonstrated that CD437 can inhibit the growth of both androgen-dependent andindependent HPC cells despite their resistance to ATRA. Importantly, CD437 was more eective in inhibiting the growth of androgen-independent cells (DU145 and PC-3) than androgen-dependent cells (LNCaP). CD437 caused apoptosis in both types of HPC cells. However, the two androgen-independent DU145 and PC-3 cells were more susceptible than androgen-dependent LNCaP cells to CD437-induce apoptosis. In a recent study, we demonstrated that another synthetic retinoid 4HPR, which has been used in several clinical trials, induced apoptosis in the same HPC cells. However, this eect was exerted only at a relatively high concentration (41 mM) and was relatively weaker in androgen-independent HPC cells than in androgen-dependent ones (Sun et al., 1999b) . More recently, another retinopid CD271 was found to exert potent eects on the growth of androgen-independent HPC cells (Lu et al., 1999) . Our study con®rmed and extended their results in that we have shown that CD437 is almost 10 times more potent than CD271 in inhibiting the growth of HPC cells. We do not know why CD437 is more potent than CD271 in induction of apoptosis. Their structures are very similar and their ability to transactivate RARE-reporter gene constructs is comparable with CD271 being more potent on RARb and equipotent on RARg (Sun et al., 1997a) . Recently, it was suggested that a 95 kD protein may mediate the eect of CD437 on apoptosis (Fontana et al., 2000) . It would be of interest to determine whether CD271 has lower anity for this protein than CD437 that could explain its lower potency as an apoptosis inducer.
Our ®ndings diers from those reported by Liang et al. (1999) who did not ®nd that PC-3 cells were more sensitive than LNCaP cells to CD437 treatment. The discrepancy is not clear. Results that we obtained by both TUNEL and ELISA clearly indicate that androgen-independent cell lines especially DU145 are more sensitive than androgen-dependent cell line LNCaP to CD437-induced apoptosis. In addition, previous work by Lu et al. (1999) and our current work indicate that CD271, an analog of CD437, is also more eective in androgen-independent cells. We are not sure whether the dierence between our and Liang et al.'s results are due to the dierent culture conditions or dierences between cell lines propagated in dierent laboratories.
It appears that CD437 has several advantages over 4HPR and CD271 in that it induced apoptosis at lower concentration (51 mM) and had a preferential eect on androgen-independent HPC cells. These properties of CD437 may have important clinical implications because the major reason for the failure of androgen ablation therapy for prostate cancer is tumor cell heterogeneity, which leads eventually to the development of androgen-independent cancer in which further anti-androgen therapy is ineective (Isaacs et al., 1994; Harris and Savill, 1995) . Therefore, CD437 could be a good candidate for use in combination with androgen ablation as eective therapy for androgen-independent cancer.
Caspases play important roles in apoptosis triggered by various signals (Thornberry and Lazebnik, 1998). After 24 h, the cells were then subjected to detection of apoptosis using an ELISA as described in Materials and methods. Each column is the mean+s.d. of triplicate determinations Of the known caspases, caspase-3 is one of the strongest candidates for being a mammalian cell death-inducing protease that cleaves PARP and other vital proteins (Thornberry and Lazebnik, 1998) . Involvement of caspases in CD437-induced apoptosis in dierent types of cancer cell has been suggested previously by us (Sun et al., 1999a,c) and other groups (Piedra®ta and Pfahl, 1997; Mologni et al., 1999) . In this study, we found that CD437 activated caspase-3 and cleaved PARP in DU145 and LNCaP cells but not in PC-3 cells although all three cell lines underwent apoptosis after exposure to CD437. Moreover, the caspase-3 inhibitor Z-DEVD-FMK and the pancaspase-inhibitor Z-VAD-FMK suppressed CD437-induced apoptosis in DU145 and LNCaP cells but not in PC-3 cells. These results indicate that CD437 induces either caspase-dependent (DU145 and LNCaP) or caspase-independent (LNCaP) apoptosis in HPC cells. Previous work by Adachi et al. (1998a) indicated that CD437-induced apoptosis in human T-cell lymphoma cells also involves caspase-dependent and -independent pathways.
Wild-type p53 and its regulated genes p21, Fas, DR5, and bax have been implicated in the control of apoptosis (Miyashita et al., 1994; Burns and El-Deiry, 1999; Sheikh and Fornace, 2000) . Cells with wild-type p53 are generally susceptible to radiation or chemotherapeutic agents, whereas cells lacking wild-type p53 expression still undergo apoptosis but need relatively higher doses of radiation or chemotherapeutic drugs (Lowe et al., 1993; Lee and Bernstein, 1993) . Among the three HPC cell lines used in this study, only LNCaP cells have wild-type p53 gene (Isaacs et al., 1991; Carroll et al., 1993) . The p53 protein level was increased in LNCaP cells by CD437 early before apoptosis happened. However, DU145 and PC-3 cells with mutant p53 or p53 null were more sensitive than LNCaP to CD437. This seems to dier from our observation that lung cancer cells with wild-type p53 are more sensitive than cells with mutant p53 to CD437 (Sun et al., 1999a) . This suggests a less important role for p53 in CD437-induced apoptosis in HPC cells.
Death receptors such as Fas, DR4 and DR5, which are cell surface receptors and belong to the TNF receptor gene superfamily, transmit apoptotic signals initiated by speci®c`death ligands' such as TRAIL and FasL and, therefore, play a central role in instructive apoptosis (Ashkenazi and Dixit, 1998) . Fas and DR5 have been found to be p53-regulated genes (Muller et al., 1998; Wu et al., 1997) and may contribute to p53 mediated apoptotic signaling pathway (Burns and El-Deiry, 1999; Sheikh and Fornace, 2000) . CD437 induced DR5 expression in a p53-dependent manner in human lung cancer cells (Sun et al., 1999a,c) . In contrast, the present study has shown that DR5 expression was induced in all the HPC cells regardless of p53 status. In fact, the highest DR5 expression was observed in p53-mutated DU145 cells. Moreover, Fas expression was induced not only in LNCaP cells with wild-type p53 but also in DU145 cells carrying mutant p53. Clearly, these results suggest that p53 plays a minor role, if any in CD437-induced apoptosis in HPC cells. In addition, CD437 also induced the expression of another death receptor DR4 in DU145 cells. This is the ®rst demonstration that CD437 induces DR4 expression and p53-independent DR5 and Fas expression in human cancer cells. These results suggest that death receptors play an important role in CD437-induced apoptosis in human HPC cells. However, the contribution of each individual receptor may vary among the cell lines. It appears that Fas plays a role in CD437-induced apoptosis in LNCaP cells but not in PC-3 cells because it was not induced in the latter cells. However, all three death receptors (Fas, DR4 and DR5) may be important for CD437-induced apoptosis in DU145 cells because they were all highly induced in this cell line. These results may also account for the supersensitivity of DU145 to CD437-induced apoptosis.
The induction of the death receptors especially DR4 and DR5 by CD437 is important because both DR4 and DR5 are the receptors for the death ligand TRAIL (Ashkenazi and Dixit, 1998) . Therefore, it is plausible to expect enhanced apoptosis of HPC cells by the combination of CD437 and TRAIL. Indeed, we found that the combination of CD437 and TRAIL caused synergistic induction of apoptosis in both androgenindependent HPC cells. This ®nding suggests a potential useful strategy for treatment of HPC because TRAIL is a potent inducer of apoptosis in a variety of cancer cells (Pitti et al., 1996; Gazitt 1999 ) and has been proved to be a relatively safe agent in vivo (Ashkenazi et al., 1999; Walczak et al., 1999) . In addition, we found that DcR2, another TRAIL receptor with truncated death domain, which can compete with DR4 or DR5 for binding to TRAIL and thereby prevent cells from undergoing TRAILinduced apoptosis (Ashkenazi and Dixit, 1998) , could suppress apoptosis induced by combination of CD437 and TRAIL. This indicates that CD437 augments TRAIL induced apoptosis through upregulation of DR4 and DR5 in HPC cells. p21 induces G1 arrest by inhibiting cyclin-dependent kinase and proliferating cell nuclear antigen (PCNA)-dependent DNA replication (El-Deiry et al., 1993; Li et al., 1994) . However, its role in apoptosis remains controversial because p21 can protect cells from apoptosis (Gorospe et al., 1996a (Gorospe et al., ,b, 1997 Polyak et al., 1996; Asada et al., 1999) . Moreover, p21 can serve as a substrate for caspases and its cleavage during apoptosis may enhance cell susceptibility to apoptosis (Chai et al., 2000; Gervais et al., 1998; Levkau et al., 1998; Zhang et al., 1999) . In our study, CD437 increased the level of p21 mRNA in all three HPC cell lines. p21 protein was increased in both LNCaP and PC-3 cells, however, it exhibited only a temporary increase followed by a decrease at later times in DU145 cells. Because DU145 cells were the most susceptible to CD437-induced apoptosis and exhibited the highest caspase-3 activity and rapid PARP cleavage when exposure to CD437 among the three HPC cell lines, it is possible that the decrease of p21 protein by CD437 in DU145 cells may be due to its cleavage. Indeed, we detected cleaved p21 band after DU145 cells were exposed CD437, indicating that p21 protein is cleaved during CD437-induced apoptosis in DU145 cells. This may be another explanation for the high sensitivity of DU145 to CD437-induced apoptosis. This is also ®rst demonstration that CD437 causes p21 protein cleavage in human cancer cells.
The bcl-2 and bcl-X L gene products can inhibit apoptosis, whereas bax can promote cell death (Adams and Cory, 1998) . It has been suggested that the bcl-2 to bax ratio determines survival or death following an apoptotic stimulus (Adams and Cory, 1998) . CD437 was previously found to change the bcl-2 to bax ratio by increasing bax expression and decreasing bcl-2 expression in human breast cancer cells (Shao et al., 1995) . In HPC cells, CD437 had only minor or no eects on the expression of bcl-2, bcl-X L and bax. DU145 cells do not express bax and bcl-2 but are very sensitive to CD437-induced apoptosis whereas PC-3 and LNCaP express comparable levels of bcl-2 and bax but exhibit dierent sensitivity to CD437 treatment. Therefore, we conclude that these genes are unlikely to play roles in in CD437-induces apoptosis in HPC cells.
Oncogenes such as c-Myc (Packham and Cleveland, 1995) , c-Fos (Preston et al., 1996; Smeyne et al., 1993) and c-Jun (Sawai et al., 1995) were also implicated as mediators of apoptosis induction in some cell systems. Despite the apparent importance of c-Myc in the promotion of cell proliferation, recent studies have linked increased expression of c-Myc to increased cellular susceptibility to apoptosis or to the induction of apoptosis (Packham and Cleveland, 1995) . In our study, CD437-enhanced expression of c-Myc in DU145 and PC-3 cells but not in LNCaP cells was correlated with cellular sensitivity to CD437 treatment. In addition, the increased c-Myc expression in DU145 and PC-3 was accompanied by the induction of ODC mRNA, which has been identi®ed recently to be one of the mediators of c-Myc-induced apoptosis (Packham and Cleveland, 1994) . Therefore, these results suggest that c-Myc may function as an important mediator of CD437-induced apoptosis in DU145 and PC-3 cells.
c-Jun and c-Fos, which form either homodimers or heterodimers and bind to the DNA consensus sequence TGA(C/G)TCA (named the 12-O-tetradecanoylphorbol 13-acetate-response element) in the promoter regions of several genes, are important factors in apoptosis induction (Smeyne et al., 1993; Sawai et al., 1995; Preston et al., 1996) . Recently, c-Fos induction and AP-1 activation by CD437 has been demonstrated in human melanoma cells (Schadendorf et al., 1996) . Further, over-expression of a dominant negative c-Jun in lung cancer cells suppressed CD437-induced apoptosis (Li et al., 1998) . In this study, CD437 upregulated the expression of c-Jun and c-Fos in DU145 and PC-3 cells but not in LNCaP cells, suggesting that these protoncogenes may also play some roles in CD437-induced apoptosis in PC-3 and DU145 HPC cells.
In summary, we demonstrated that CD437 induced rapid apoptosis in HPC cells, especially in androgenindependent cells, which is mediated by either caspasedependent or independent pathway. Moreover, CD437 augmented TRAIL-or FasL-induced apoptosis, through upregulating the expression of their receptors. These ®ndings suggest a potential use of this agent in treatment of HPC. In addition, we found that multiple mechanisms involving Fas, DR4, DR5, c-Myc, c-Jun and c-Fos may contribute to CD437 induced apoptosis in dierent HPC cells.
Materials and methods
Reagents
CD437 and CD271 were provided by Dr B Shroot (Galderma R&D, Sophia Antipolis, France), and ATRA was a gift from Dr W Bollag (F. Homann-La Roche, Basel, Switzerland).
They were dissolved in DMSO at a concentration of 10 mM and stored under N 2 gas in the dark at 7808C. Recombinant soluble human FasL and Recombinant human DcR2:Fc (rhDcR2:Fc) were purchased from Alexis Biochemicals (San Diego, CA, USA). Soluble recombinant human TRAIL was purchased from Biomol (Plymouth Meeting, PA, USA). The caspase inhibitors CBZ-Val-Ala-Asp-Fluoromethyl Ketone (FMK) (Z-VAD-FMK) and CBZ-Asp-Glu-Val-Asp-FMK (Z-DEVD-FMK) and¯uorogenic caspase substrates Ac-DEVD-AFC were purchased from Enzyme System Products (Livermore, CA, USA).
Cell culture and cell survival assay HPC cell lines PC-3, DU145 and LNCaP were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The characteristics of these cell lines and cell culture conditions were reported previously (Sun et al., 1999b) . For evaluation of cell survival, cells were seeded at densities of 2000 ± 6000 cells per well in 96-well cluster tissue culture plates and treated on the next day with dierent concentrations of retinoids. Control cultures received the same amount of DMSO as treated cultures (40.1%). After 5 days treatment, cell number was determined using the Alamar Blue TM reagent (Alamar, Westlake, OH, USA) following the manufacturer's instructions. Brie¯y, 20 ml Alamar Blue reagent was added to each tested well (200 ml medium/well). After the plates were incubated for 3 h at 378C in a incubator with 5% CO 2 and 90% humidity, Thē uorescence intensity was measured at 590 nm after excitation at 560 nm using a CytoFluor Multi-Well Plate Reader Series 400 (PerSeptive Biosystems, Framingham, MA, USA). The drug concentration decreasing cell number by 50% (IC 50 ) was determined from dose response curves.
Apoptosis assay
Apoptosis was determined by the TUNEL-¯ow cytometry method using an APO-DIRECT TM kit (Phoenix Flow Systems, Inc. San Diego, CA, USA) or by using an ELISA kit (Roche Molecular Biochemicals, Indianapolis, IN, USA) following the manufacturer's directions.
Measurement of caspase-3 activity
Cells were plated onto 10-cm diameter dishes 1 day before treatment. After the cells were exposed to CD437 for dierent times, both¯oating and attached cells were harvested by trypsinization and counted. One million cells per treatment were used for measurement of caspase-3 activity as described previously (Deveraux et al., 1999) .
RNA purification and Northern blotting
Puri®cation of total cellular RNA from adherent cells and Northern blotting were performed as previously described (Sun et al., 1997a) . JAC.1 plasmid containing mouse c-Jun cDNA, pMK934 plasmid containing mouse ODC cDNA and GST-CIP1 plasmid containing human p21 cDNA were purchased from the ATCC. pBK28 plasmid containing human c-Fos cDNA and pSVc-myc-1 plasmid containing mouse c-Myc cDNA were obtained from Dr P Chiao (MD Anderson Cancer Center, Houston, TX, USA). pCR-KillerRace-6 plasmid containing human Killer/DR5 cDNA was provided by Dr WS El-Deiry (University of Pennsylvania School of Medicine, Philadelphia, PA, USA). Human Fas cDNA and DR4 fragments were purchased from Alexis Cop. glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was purchased from Ambion Inc. (Austin, TX, USA).
Protein extraction and Western blotting
The preparation of whole cell lysates, performance of Western blotting, and the antibodies except for PARP antibody used in this study were described previously (Sun et al., 1999b) . Rabbit polyclonal PARP antibody that recognizes only 89 kD cleaved PARP was purchased from New England Biolabs, Inc. (Beverly, MA, USA).
